Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening

被引：169

作者：

Lindfors, L ^{[1
]}

Skantze, P

Skantze, U

Rasmusson, M

Zackrisson, A

Olsson, U

机构：

[1] AstraZeneca R&D, Pharmaceut & Analyt R&D, Ecpt Formulat, SE-43183 Molndal, Sweden

[2] Lund Univ, SE-22100 Lund, Sweden

来源：

LANGMUIR | 2006年 / 22卷 / 03期

关键词：

D O I：

10.1021/la0523661

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Amorphous drug nanosuspensions are prone to particle growth due to Ostwald ripening. By incorporating a second component of extremely low aqueous solubility, Ostwald ripening can be inhibited. These studies indicate that to inhibit ripening, the drug/inhibitor mixture (in the particles) must form a single phase. The drug/inhibitor mixture can be characterized by the interaction parameter chi using the Bragg-Williams theory, in which single phase mixtures are obtained for chi < 2. The chi parameter can be calculated from the (crystalline) solubility of the drug in the inhibitor, provided the inhibitor is a liquid, and the melting entropy and temperature of the drug.

引用

页码：906 / 910

页数：5

共 16 条

[1] Formation of colloidal dispersions of organic materials in aqueous media by solvent shifting [J].

Brick, MC ;

Palmer, HJ ;

Whitesides, TH .

LANGMUIR, 2003, 19 (16) :6367-6380

[2]

GASSMANN P, 1994, EUR J PHARM BIOPHARM, V40, P64

[3] OSTWALD RIPENING IN 2-COMPONENT DISPERSE PHASE SYSTEMS - APPLICATION TO EMULSION STABILITY [J].

KABALNOV, AS ;

PERTZOV, AV ;

SHCHUKIN, ED .

COLLOIDS AND SURFACES, 1987, 24 (01) :19-32

[4] OSTWALD RIPENING THEORY - APPLICATIONS TO FLUOROCARBON EMULSION STABILITY [J].

KABALNOV, AS ;

SHCHUKIN, ED .

ADVANCES IN COLLOID AND INTERFACE SCIENCE, 1992, 38 :69-97

[5]

Lannibois H, 1997, J PHYS II, V7, P319, DOI 10.1051/jp2:1997128

[6]

LIFSHITS IM, 1958, ZH EKSP TEOR FIZ, V35, P479

[7]

Lifshitz I.M., 1959, SOV PHYS JETP, V35, P331

[8] Amorphous drug nanosuspensions.: 2.: Experimental determination of bulk monomer concentrations [J].

Lindfors, L ;

Forssén, S ;

Skantze, P ;

Skantze, U ;

Zackrisson, A ;

Olsson, U .

LANGMUIR, 2006, 22 (03) :911-916

[9] Drug-like properties and the causes of poor solubility and poor permeability [J].

Lipinski, CA .

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) :235-249

[10] Nanosizing: a formulation approach for poorly-water-soluble compounds [J].

Merisko-Liversidge, E ;

Liversidge, GG ;

Cooper, ER .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 18 (02) :113-120

← 1 2 →